In an adult patient who mistakenly received 100 mg intramuscular promethazine (Phenergan), what adverse effects and clinical signs should be monitored?

Immediate Monitoring for Promethazine 100 mg IM Overdose

This patient received 4 times the maximum recommended single dose and requires immediate, intensive monitoring for life-threatening complications, particularly respiratory depression, severe CNS depression, neuroleptic malignant syndrome, and extrapyramidal symptoms.

Critical Adverse Effects Requiring Immediate Monitoring

1. Respiratory Depression (HIGHEST PRIORITY)

Monitor continuously for at least 24 hours given promethazine's 9-16 hour plasma half-life 1, 2, 3:

• Continuous pulse oximetry and respiratory rate monitoring
• Watch for decreased respiratory rate, shallow breathing, apnea
• The FDA label explicitly warns of potentially fatal respiratory depression, especially at high doses 3
• This is the most dangerous complication at this dose level
• Be prepared for immediate airway management and ventilatory support

2. Central Nervous System Depression

The patient received a massive overdose (usual dose is 12.5-25 mg; maximum total dose typically 25-100 mg) 1, 2:

• Profound sedation/somnolence - expect significant CNS depression
• Delirium and confusion - occurred in 2 of 100 patients receiving 25-100 mg IM in the Findlay study 1
• Altered mental status - monitor Glasgow Coma Scale
• Paradoxical agitation or hyperexcitability 3
• At 100 mg, probability of delirium is approximately 55% based on dose-response data 4

3. Cardiovascular Effects

Monitor vital signs every 15-30 minutes initially 1, 2, 3:

• Hypotension - promethazine has strong alpha-adrenergic inhibitory effects
• Tachycardia or bradycardia
• Continuous cardiac monitoring recommended
• Blood pressure instability

4. Neuroleptic Malignant Syndrome (NMS)

This is a potentially fatal complication that can occur with phenothiazines 1, 2, 3, 5:

Monitor for the tetrad:

• Hyperpyrexia (high fever)
• Muscle rigidity
• Altered mental status
• Autonomic instability (irregular pulse/BP, tachycardia, diaphoresis, cardiac dysrhythmias)

Critical caveat: NMS can develop even with standard doses and may occur under general anesthesia 5. The diagnosis is clinical - CPK levels may be normal despite NMS 5.

5. Extrapyramidal Symptoms (EPS)

Promethazine is a phenothiazine with dopamine-blocking properties 1, 2:

• Restlessness and akathisia
• Oculogyric crisis (involuntary upward eye deviation)
• Torticollis (neck muscle spasms)
• Tongue protrusion
• Dystonic reactions
• These can range from mild restlessness to severe crisis 1, 2, 3

6. Anticholinergic Effects

Monitor for anticholinergic toxicity 1, 2:

• Dry mouth
• Blurred vision, diplopia
• Urinary retention - check bladder distension
• Confusion/delirium (overlaps with CNS depression)
• Tachycardia
• Hyperthermia

7. Seizures

Promethazine lowers seizure threshold 3:

• Monitor for seizure activity
• Particularly concerning if patient has underlying seizure disorder
• Risk increased at high doses

8. Local Tissue Complications

Although given IM (the preferred route), monitor injection site 2, 3:

• Pain, burning, erythema at injection site
• Swelling
• Signs of tissue irritation
• IM is safer than IV, but tissue damage can still occur

Monitoring Timeline

First 4-6 Hours (Peak Effect Period):

• Continuous respiratory monitoring
• Vital signs every 15-30 minutes
• Continuous cardiac monitoring
• Neurological checks every 30 minutes
• Temperature monitoring

6-16 Hours (Duration of Action):

• Continue respiratory monitoring
• Vital signs every 1-2 hours
• Ongoing neurological assessment
• Watch for delayed complications

Up to 24 Hours:

• Extended observation given the 9-16 hour half-life 1
• Monitor for recurrence of symptoms
• Watch for development of NMS (can be delayed)

Key Clinical Pitfalls

1. Do not assume the patient is "just sleeping" - distinguish between therapeutic sedation and dangerous respiratory depression
2. NMS can develop hours after administration - maintain vigilance beyond initial presentation
3. Extrapyramidal symptoms may be mistaken for anxiety or agitation - recognize and treat appropriately
4. Normal CPK does not rule out NMS - diagnosis is clinical 5
5. The long half-life means effects can persist or worsen - do not discharge prematurely

Supportive Management Considerations

• Maintain airway, breathing, circulation
• IV access for potential interventions
• Consider activated charcoal if oral co-ingestion suspected (though IM route bypasses GI tract)
• Diphenhydramine 25-50 mg IV for extrapyramidal symptoms if they develop
• Benzodiazepines for severe agitation if needed (use cautiously given additive CNS depression)
• Cooling measures if hyperthermia develops
• Dantrolene and bromocriptine for confirmed NMS

This medication error represents a serious overdose requiring ICU-level monitoring and immediate availability of advanced airway management.